Background: Acute regression has been reported in some individuals with Down syndrome (DS), typically occurring between the teenage years and mid to late 20s. Characterized by sudden, and often unexplained, reductions in language skills, functional living skills and reduced psychomotor activity, some individuals have been incorrectly diagnosed with Alzheimer’s disease (AD). Methods: This paper compares five individuals with DS who previously experienced acute regression with a matched group of 15 unaffected individuals with DS using a set of AD biomarkers. Results: While the sample was too small to conduct statistical analyses, findings suggest there are possible meaningful differences between the groups on proteomics biomarkers (e.g., NfL, total tau). Hippocampal, caudate and putamen volumes were slightly larger in the regression group, the opposite of what was hypothesized. A slightly lower amyloid load was found on the PET scans for the regression group, but no differences were noted on tau PET. Conclusions: Some proteomics biomarker findings suggest that individuals with DS who experience acute regression may be at increased risk for AD at an earlier age in comparison to unaffected adults with DS. However, due to the age of the group (mean 38 years), it may be too early to observe meaningful group differences on image-based biomarkers.
Alzheimer’s disease (AD) affects an estimated 6.9 million older adults in the United States and is projected to impact as many as 13.8 million people by 2060. As studies continue to search for ways to combat the development and progression of AD, it is imperative to ensure that confident diagnoses can be made before the onset of severe clinical symptoms and new therapies can be evaluated effectively. Tau positron emission tomography (PET) has emerged as one method that may be capable of both, given its ability to recognize the presence of tau, a primary pathologic hallmark of AD; its usefulness in determining the spatial distribution of tau, which is necessary for differentiating AD from other tauopathies; and its association with measures of cognition. This review aims to evaluate the scope of tau PET’s utility in clinical trials and practice. Firstly, the potential of using tau PET for differential diagnoses, distinguishing AD from other dementias, is considered. Next, the value of tau PET as a tool for staging disease progression is investigated. Finally, tau PET as a prognostic method for identifying the individuals most at risk of cognitive decline and, therefore, most in need of, and likely to benefit from, intervention, is discussed.